Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Silence Therapeutics (SLN) Non-Current Receivables (2019 - 2020)

Silence Therapeutics' Non-Current Receivables history spans 2 years, with the latest figure at $40.9 million for Q2 2020.

  • On a quarterly basis, Non-Current Receivables changed N/A to $40.9 million in Q2 2020 year-over-year; TTM through Jun 2020 was $40.9 million, a N/A change, with the full-year FY2019 number at $5107.4, changed N/A from a year prior.
  • Non-Current Receivables hit $40.9 million in Q2 2020 for Silence Therapeutics, up from $5142.9 in the prior quarter.
  • Over the last five years, Non-Current Receivables for SLN hit a ceiling of $40.9 million in Q2 2020 and a floor of $5142.9 in Q4 2019.